In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population

The FDA Oncologic Drugs Advisory Committee expressed decisive support for the agency’s view that data from trials of checkpoint inhibitors performed in mainland China aren’t applicable to the U.S. population.